Novartis Acquisition Would Expand Manufacturing Capacity for Cell and Gene Therapies
Gene Therapy to Restore Vision for People With Retinal Disease Approved in EU
The European Commission (EC) has approved Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene and who have enough viable retinal cells. The authorization is valid in all 28 member states of the EU, as well as Iceland, Liechtenstein, and Norway.…